Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover - Pharmaceutical Technology

This acquisition marks Eli Lilly’s first move into the psychedelic space as the pharma curates a diversified pipeline. This acquisition marks Lilly’s first move into the psychedelic space as the pharma curates a diversified pipeline. Through the acquisition, Lilly will acquire AtaiBeckley’s range of psychedelic therapies for mental health conditions. Credit: Elena Pimonova / Shutterstock.com. Following its high-profile dealmaking spree in the first portion of 2026, Eli Lilly has struck again – this time through a multi-billion-dollar acquisition of psychedelic biotech, AtaiBeckley. Through the deal, which will set Lilly back $2.8bn upfront, the pharmaceutical giant will absorb AtaiBeckley’s three-strong clinical-stage…

Annabel Kartal Allen · 2026-07-16

This acquisition marks Eli Lilly’s first move into the psychedelic space as the pharma curates a diversified pipeline.

Source: Pharmaceutical Technology